Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BYSI
stocks logo

BYSI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Beyondspring Inc (BYSI.O) is -6.03, compared to its 5-year average forward P/E of -3.36. For a more detailed relative valuation and DCF analysis to assess Beyondspring Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.36
Current PE
-6.03
Overvalued PE
-0.95
Undervalued PE
-5.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.08
Undervalued EV/EBITDA
-3.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29.01
Current PS
0.00
Overvalued PS
79.59
Undervalued PS
-21.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 343.22% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 343.22% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

BYSI News & Events

Events Timeline

(ET)
2025-11-12
07:02:16
BeyondSpring announces Q3 earnings per share of 4 cents, compared to a loss of 5 cents in the same period last year.
select
2025-08-13 (ET)
2025-08-13
08:07:23
BeyondSpring reports Q2 EPS (10c) vs (4c) last year
select
2025-07-07 (ET)
2025-07-07
07:15:43
BeyondSpring announces publication of human clinical study on plinabulin
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
09-15Newsfilter
Transcript of BeyondSpring Inc. (BYSI) Annual Shareholders Meeting for 2025

  • Meeting Overview: The 2025 Annual Shareholders Meeting of BeyondSpring Inc. was presided over by Co-Founder and CEO Lan Huang, with a quorum established as more than a majority of shareholders were present either virtually or by proxy.

  • Voting Agenda: The sole item on the agenda was the ratification of CBIZ as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with shareholders invited to vote through a web portal.

[object Object]
Preview
9.5
08-13Newsfilter
BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

  • Plinabulin's Role in Cancer Treatment: BeyondSpring Inc. presented promising data on Plinabulin, a first-in-class agent that enhances immune response in NSCLC patients who have progressed after PD-1/L1 therapies, showing significant survival benefits and potential to redefine cancer treatment standards.

  • SEED Therapeutics Advancements: SEED Therapeutics received FDA clearance for its RBM39 degrader ST-01156, which targets aggressive cancers, while also announcing leadership changes to accelerate development efforts in targeted protein degradation therapies.

[object Object]
Preview
9.0
06-03Newsfilter
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

  • Study Results: BeyondSpring Inc. presented interim Phase 2 data showing that Plinabulin combined with pembrolizumab and docetaxel resulted in a median progression-free survival of 6.8 months and a disease control rate of 77.3% in metastatic non-small cell lung cancer patients who had progressed on PD-1/L1 therapies.

  • Therapeutic Potential: The findings suggest that Plinabulin may effectively re-sensitize tumors to immunotherapy, addressing the significant unmet need for treatment options in patients who have developed resistance to checkpoint inhibitors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Beyondspring Inc (BYSI) stock price today?

The current price of BYSI is 1.93 USD — it has increased 1.58 % in the last trading day.

arrow icon

What is Beyondspring Inc (BYSI)'s business?

BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.

arrow icon

What is the price predicton of BYSI Stock?

Wall Street analysts forecast BYSI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BYSI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Beyondspring Inc (BYSI)'s revenue for the last quarter?

Beyondspring Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Beyondspring Inc (BYSI)'s earnings per share (EPS) for the last quarter?

Beyondspring Inc. EPS for the last quarter amounts to -0.04 USD, decreased -20.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Beyondspring Inc (BYSI)'s fundamentals?

The market is revising No Change the revenue expectations for BYSI for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 3.76%.
arrow icon

How many employees does Beyondspring Inc (BYSI). have?

Beyondspring Inc (BYSI) has 40 emplpoyees as of December 05 2025.

arrow icon

What is Beyondspring Inc (BYSI) market cap?

Today BYSI has the market capitalization of 79.37M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free